ALX Oncology Holdings Inc. (ALXO) financial statements and ratios from SEC XBRL: revenue $3.96M (TTM), net margin -2565.5%, revenue growth -57.7% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $3.96M |
| Net Margin | -2565.5% |
| Revenue Growth (YoY) | -57.7% |
| EPS Growth (YoY) | -26.4% |
| FCF Growth (YoY) | -31.1% |
| Price / Book | 2.01 |
| Price / Sales | 58.59 |
| FCF Yield | -50.2% |
| Altman Z-Score | -17.49 (distress) |
| Sector P/E (Healthcare) | 21.7 |
ALXO overview · ALXO earnings · ALXO KPIs · ALXO investor relations · ALXO ownership · ALXO peers · ALXO filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.